Cargando…

The Lock and Key of Medicine : Monoclonal Antibodies and the Transformation of Healthcare /

The untold story of monoclonal antibodies-the molecular heroes of biotechnology that revolutionized the diagnosis and treatment of more than fifty major diseases This book is the first to tell the extraordinary yet unheralded history of monoclonal antibodies. Often referred to as Mabs, they are unfa...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Marks, Lara, 1963- (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New Haven [Connecticut] ; London : Yale University Press, [2015]
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Ii 4500
001 EBSCO_ocn910553652
003 OCoLC
005 20231017213018.0
006 m o d
007 cr cnu|||unuuu
008 150602t20152015ctua ob 001 0 eng d
010 |z  2015930850 
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d N$T  |d IDEBK  |d E7B  |d YDXCP  |d CDX  |d OCLCF  |d EBLCP  |d OH1  |d KSU  |d NRC  |d OCLCO  |d OCLCQ  |d OCLCA  |d BAL  |d BUF  |d OCLCO  |d WRM  |d OCLCO  |d GILDS  |d OCLCO  |d AGLDB  |d OCLCO  |d IGB  |d OCLCO  |d INT  |d AUW  |d BTN  |d MHW  |d INTCL  |d SNK  |d OCLCO  |d AU@  |d OCLCQ  |d A6Q  |d G3B  |d S8I  |d S8J  |d STF  |d JBG  |d D6H  |d M8D  |d OCLCO  |d OCLCQ  |d OCLCA  |d DEGRU  |d OCLCO  |d OCLCQ  |d INARC 
019 |a 1058624084  |a 1096218169  |a 1359006612 
020 |a 9780300213522  |q (electronic bk.) 
020 |a 0300213522  |q (electronic bk.) 
020 |z 9780300167733  |q (print) 
020 |z 0300167733 
029 1 |a AU@  |b 000062431101 
029 1 |a AU@  |b 000069535469 
035 |a (OCoLC)910553652  |z (OCoLC)1058624084  |z (OCoLC)1096218169  |z (OCoLC)1359006612 
050 4 |a QR186.85 
060 4 |a QW 575.5.A6 
072 7 |a HEA  |x 039000  |2 bisacsh 
072 7 |a MED  |x 014000  |2 bisacsh 
072 7 |a MED  |x 022000  |2 bisacsh 
072 7 |a MED  |x 112000  |2 bisacsh 
072 7 |a MED  |x 045000  |2 bisacsh 
082 0 4 |a 616.0793  |2 23 
049 |a UAMI 
100 1 |a Marks, Lara,  |d 1963-  |e author. 
245 1 4 |a The Lock and Key of Medicine :  |b Monoclonal Antibodies and the Transformation of Healthcare /  |c Lara V. Marks. 
264 1 |a New Haven [Connecticut] ;  |a London :  |b Yale University Press,  |c [2015] 
264 4 |c Ã2015 
300 |a 1 online resource :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
505 0 |a Illustrations -- Preface -- Acknowledgments -- Abbreviations -- Hunting for the Elusive "Magic Bullet" -- A Hesitant Start Patents, Politics, and Process -- Breakthroughs at the Bench -- The First Medical Applications -- Joy, Disappointment, Determination Early Clinical Tests -- The Wild West of Antibody Commercialization -- The Challenge of Monoclonal Antibody Drugs -- Antibody Engineering: A Renaissance for Mab Therapeutics -- Blockbuster Mab Drugs -- A Quiet Revolution: The Legacy of Monoclonal Antibodies -- Notes -- Glossary -- Bibliography -- Index. 
588 0 |a Vendor-supplied metadata. 
504 |a Includes bibliographical references and index. 
520 |a The untold story of monoclonal antibodies-the molecular heroes of biotechnology that revolutionized the diagnosis and treatment of more than fifty major diseases This book is the first to tell the extraordinary yet unheralded history of monoclonal antibodies. Often referred to as Mabs, they are unfamiliar to most nonscientists, yet these microscopic protein molecules are everywhere, quietly shaping our lives and healthcare. Discovered in the mid-1970s in the laboratory where Watson and Crick had earlier unveiled the structure of DNA, Mabs have radically changed understandings of the pathways of disease. They have enabled faster, cheaper, and more accurate clinical diagnostic testing on a vast scale. And they have played a fundamental role in pharmaceutical innovation, leading to such developments as recombinant interferon and insulin, and personalized drug therapies such as Herceptin. Today Mabs constitute six of the world's top ten blockbuster drugs and make up a third of new introduced treatments. Lara V. Marks recounts the risks and opposition that a daring handful of individuals faced while discovering and developing Mabs, and she addresses the related scientific, medical, technological, business, and social challenges that arose. She offers a saga of entrepreneurs whose persistence and creativity ultimately changed the healthcare landscape and brought untold relief to millions of patients. Even so, as Marks shows, controversies over Mabs remain, and she examines current debates over the costs and effectiveness of these innovative drugs. 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Monoclonal antibodies. 
650 2 |a Antibodies, Monoclonal  |x therapeutic use 
650 2 |a Antibodies, Monoclonal 
650 6 |a Anticorps monoclonaux. 
650 7 |a HEALTH & FITNESS  |x Diseases  |x General.  |2 bisacsh 
650 7 |a MEDICAL  |x Clinical Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Diseases.  |2 bisacsh 
650 7 |a MEDICAL  |x Evidence-Based Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Internal Medicine.  |2 bisacsh 
650 7 |a Monoclonal antibodies.  |2 fast  |0 (OCoLC)fst01025547 
655 7 |a History.  |2 fast  |0 (OCoLC)fst01411628 
856 4 0 |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1000448  |z Texto completo 
938 |a De Gruyter  |b DEGR  |n 9780300213522 
938 |a Coutts Information Services  |b COUT  |n 31712994 
938 |a EBL - Ebook Library  |b EBLB  |n EBL3446668 
938 |a ebrary  |b EBRY  |n ebr11060284 
938 |a EBSCOhost  |b EBSC  |n 1000448 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n cis31712994 
938 |a YBP Library Services  |b YANK  |n 12457885 
938 |a Internet Archive  |b INAR  |n lockkeyofmedicin0000mark 
994 |a 92  |b IZTAP